Clinical and hemodynamic outcomes of hemoperfusion therapy for COVID-19 patients: a historical cohort study.

Background: Inflammation exacerbates COVID-19. Hemoperfusion removes toxins and inflammatory elements from the circulation; however, its effect on COVID-19 is uncertain. The clinical and hemodynamic outcomes of COVID-19 patients after hemoperfusion are the focus of this study.

Methods: This historical cohort study was conducted on a group of 320 individuals diagnosed with COVID-19 between March 2020 and June 2022 in Zanjan, Iran. The required variables were extracted from the patient's hospital records using a pre-established checklist. The chi-square test, Fisher's exact test, the Mann-Whitney test, and the repeated measure ANOVA test were employed. The data analysis programme employed was SPSS version 26.

Results: Participants in the study had a mean age of 64.82 ± 12.46 years. The association between exposure to hemoperfusion and clinical status, degree of lung involvement, and intubation was found to be statistically significant (P-value < 0.05). There were statistically significant differences between the two groups in the mean GCS, platelet count, WBC, hemoglobin level, breaths per minute, systolic blood pressure, the number of neutrophils and lymphocytes and SPO2 at different time points (P-value group*time < 0.05).

Conclusion: Patients with severe COVID-19 who undergo hemoperfusion treatment appear to experience improvements in both their clinical and hemodynamic status. We need to conduct additional research in order to verify this.